12:00 AM
 | 
May 24, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Busulfex busulfan: Phase II; marketed for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell t

Orphan Medical Inc. (ORPH), Minneapolis, Minn.
Product: Busulfex busulfan
Business: Cancer
Therapeutic category: Adjunct, Cytotoxic
Target: DNA
Description: Intravenous busulfan
Indication: Treat non-Hodgkin's lymphoma...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >